Fast and responsive
Article enhancements
Global readership
Flexible Open Access solutions
Exceptional service
A proven track record of fast and flexible publishing solutions
With over 50 years of publishing expertise in medical journals, Adis have built a legacy of trust and excellence. While our core focus is on drugs, our editorial scope extends to medical devices, diagnostics, and other therapeutic interventions.
Publish with Adis
Integrity & Impact
Over 30 peer-reviewed journals with strong and trusted metrics and large global readership
Tailored options
Flexible open access and personalised digital enhancements
Speed without compromise
Peer review in as little as 2 weeks for our Rapid+ Journals, and publication in 30 days with our VIP service.
People-powered support
Concierge-level author care from submission to post-publication.
Editorial Board member and author
Author
Pharmaceutical funder
Pharmaceutical funder
Editorial Board member and author
Whether you arean authora librariana researchera reader
Adis is your trusted partner in advancing medical knowledge
Whether you arean authora librariana researchera reader
Adis is your trusted partner in advancing medical knowledge
Global reach. Personal touch
As part of Springer Nature, we support a global audience working in the pharmaceutical and biotech industry; medical research, practice and teaching; drug regulation and reimbursement; and adjacent markets such as finance and consulting.
Discover the full Adis portfolio
Adis Publications include a collection of over 30 peer-reviewed medical journals spanning all therapeutic areas, and a newsletter focused on drug safety.
Trusted by our authors and valued by our readers, Adis Journals deliver timely, high-impact, and expertly reviewed content. Whether you are publishing your research or are staying informed, Adis connects you to the latest in drug development and clinical science.
We are here for you!
If you want to chat about publishing with Adis then get in touch.
Clare CookAdis Editorial Manager
Clare joined Springer Nature in 2009 and has worked in various capacities on the Adis journals - based out of our Chester UK office - launching new journals, commissioning content, and developing novel article types and digital enhancements.
She currently manages the 11 journals in the Rapid+ side of the Adis portfolio, overseeing the editorial processes and journal team, working closely with the business development team and with industry contacts, attending and speaking at publishing conferences, and working on strategy and innovations across the journal portfolio.
She currently manages the 11 journals in the Rapid+ side of the Adis portfolio, overseeing the editorial processes and journal team, working closely with the business development team and with industry contacts, attending and speaking at publishing conferences, and working on strategy and innovations across the journal portfolio.
Lydia AlbornEditor
Lydia joined Springer Nature in 2017 as an Editorial Administrator for Adis journals and has worked across the portfolio in her time. She now serves as Managing Editor for Oncology content in Oncology and Therapy and Advances in Therapy. She works closely with the Adis team to ensure rapid publication timelines, scientific integrity, and personalised service.
A strong advocate for reducing health inequalities, Lydia promotes equitable reporting of sex, gender, race, and ethnicity in research. She also champions innovation in scholarly communication, contributing to the development of novel article types and sharing insights at publishing conferences and beyond.
A strong advocate for reducing health inequalities, Lydia promotes equitable reporting of sex, gender, race, and ethnicity in research. She also champions innovation in scholarly communication, contributing to the development of novel article types and sharing insights at publishing conferences and beyond.
